Steven Cohen acquired 1.27 Million Apellis Pharmaceuticals shares worth $21.9 Million. That's 0.07% of their equity portfolio (327th largest holding). The investor owns 1.01% of the outstanding Apellis Pharmaceuticals stock. The first Apellis Pharmaceuticals trade was made in Q4 2018. Since then Steven Cohen bought shares eight more times and sold shares on seven occasions. The investor's estimated purchase price is $38.3 Million, resulting in a loss of 43%.